Chasserot-Golaz S, Parcollet P, Beck G
Institut de Biologie Moléculaire et Cellulaire du CNRS, Strasbourg, France.
J Steroid Biochem. 1989;34(1-6):473-8. doi: 10.1016/0022-4731(89)90130-1.
Microsomal P450 monooxygenases contribute actively to the biotransformation of the antiglucocorticoid RU38486, an 11 beta-substituted nor-steroid. Pretreatment of adult rats by inducers of specific forms, belonging to different P450 subfamilies, affects the ability of liver microsomes to metabolize RU38486. Phenobarbital and pregnenolone 16 alpha-carbonitrile increase the metabolic activity of liver microsomes whereas methylcholanthrene decreases their capacity to oxidize the steroid. Thus P450 forms IIIA, IIB1,2 and IIC7 are good candidates to be involved in the degradation of this peculiar molecule. Our study has been completed by investigating whether RU38486 would influence the P450 spectrum. Whereas the treatment of rats with either a glucocorticoid (cortisol, dexamethasone) or an antiglucocorticoid (pregnenolone 16 alpha-carbonitrile) has been shown to induce the P450 activity by increasing the hepatic concentration of form IIIA, we observed a slight decrease of the P450 activity by treating the animals with RU38486. Moreover RU38486 was able to antagonize the P450 induction by the other steroids as well as it inhibits the synthesis of various liver enzymes induced by glucocorticoids (for instance tyrosine aminotransferase). These findings may be important for the therapeutic use of RU38486 since its inhibitory effect on P450 activity may be at the origin of drug interactions by modifying the endogenous hormonal status.
微粒体P450单加氧酶积极参与抗糖皮质激素RU38486(一种11β-取代的去甲类固醇)的生物转化。用属于不同P450亚家族的特定形式的诱导剂对成年大鼠进行预处理,会影响肝微粒体代谢RU38486的能力。苯巴比妥和孕烯醇酮16α-腈可增加肝微粒体的代谢活性,而甲基胆蒽则降低其氧化该类固醇的能力。因此,P450 IIIA、IIB1、2和IIC7形式很可能参与了这种特殊分子的降解。我们通过研究RU38486是否会影响P450谱完成了这项研究。虽然已证明用糖皮质激素(皮质醇、地塞米松)或抗糖皮质激素(孕烯醇酮16α-腈)处理大鼠可通过增加IIIA形式的肝浓度来诱导P450活性,但我们观察到用RU38486处理动物会使P450活性略有下降。此外,RU38486能够拮抗其他类固醇对P450的诱导作用,并且它还抑制糖皮质激素诱导的各种肝酶的合成(例如酪氨酸转氨酶)。这些发现对于RU38486的治疗用途可能很重要,因为其对P450活性的抑制作用可能通过改变内源性激素状态而成为药物相互作用的根源。